SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice.

Authors:
Jurczak MJ; Saini S; Ioja S; Costa DK; Udeh N and 3 more

Journal:
Islets

Publication Year: 2018

DOI:
10.1080/19382014.2018.1503027

PMCID:
PMC6284495

PMID:
30118626

Journal Information

Full Title: Islets

Abbreviation: Islets

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure of potential conflicts of interest Jean Whaley is currently an employee of Janssen Research and Development and a former employee of Bristol-Myers Squibb, where she contributed to the development of the SGLT2 inhibitor dapagliflozin. All other authors declare they have no competing interests."

Evidence found in paper:

"This work was supported by the National Institutes of Health [DK-099402 M.J.J.; DK-110181 and DK-092606 R.G.K] and Astrazeneca/Bristol-Myers Squibb."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025